Oncopeptides : Redeye Growth Day 2021 presentation

Oncopeptides corporate presentation

Redeye growth day 2021, June 2, 2021 Anders Martin-Löf, CFO

Disclaimer

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Oncopeptides AB (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the "Information").

On 26 February 2021, the U.S. Food and Drug Administration ("FDA") approved PEPAXTO® (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. This indication has been granted under accelerated approval based upon data from the HORIZON study. Melflufen is not approved by any other registration authorities.

Melflufen is an abbreviated form of the international non-proprietary name (INN) melphalan flufenamide

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future.

No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company's expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

2

Oncopeptides at a glance

Fully integrated biotech company with first product launched in March

	Innovative drug	Comprehensive clinical development	First commercial
	discovery	program	launch in the U.S.
•	Targeted therapies for	• Initial focus on $ 19 B Multiple Myeloma market	• PEPAXTO launched by own sales force
	hematological diseases	• Broad supportive MM clinical program, entering	in the US mid-March
•	Drug candidates from peptide	into new indications	• EMA submission April 16
	drug conjugate platform (PDC)	• Positive phase 3 OCEAN data presented May 25

3

PEPAXTO granted accelerated approval on February 26 by FDA

Offers hope to RRMM patients with high unmet needs

• Initial label targets patients with relapsed or refractory multiple myeloma
• • whose disease is refractory to at least;
  • • one proteasome inhibitor,
    • one immuno-modulatory agent
    • one CD38-directed antibody,
  • who have received at least four prior lines of therapy
• FDA approval based on a sub population of the HORIZON study (n=97) with high unmet medical of which 41% had extramedullary disease (EMD)
• Commercial drug available to patients beginning from March 15

4

PEPAXTO off to a strong start first six weeks

Revenue Metrics		Field Team Metrics

$5.6M

~100

>700

>90%

>90%

97%

Net sales in	# of accounts	# of 20 mg	Top tier	Customer	Payer
first 6 weeks	using product	vials shipped	customers	awareness	coverage

5